Pharmaceutical manufacturer: Stada prepares a billion-dollar exchange in autumn

The pharmaceutical manufacturer Stada takes a new attempt for a billion -dollar IPO in Frankfurt. “We are preparing an IPO in autumn if the framework is correct,” said Stada boss Peter Goldschmidt of the German Press Agency.

Unlike in spring, the environment at the financial markets is currently more stable. “In addition, it is an advantage in the current environment that we have almost no business in the USA,” said Goldschmidt.

Trump thwarted the invoice

Stada, based in Bad Vilbel near Frankfurt, wanted to go to the stock exchange in April. However, the plans were postponed because the courses fluctuated with Trump’s customs threats. The IPO in the second attempt – for which October stands in the room – is now to be announced formally in a few days.

Stada, known for the GRIPPOSTAD and the Silomat cough juice, could be rated at around ten billion euros. This would make Stada one of the largest stock exchange tours in Europe this year and at least one candidate for the MDAX.

IPOs are rare in Germany: This summer, two candidates-the online car participant Autodoc and medical technology bidder Brainlab-have canceled their plans.

It is not known how many shares the Stada owners, the financial investors Bain Capital and Cinven, could be handed over during an IPO. They had bought the medicine manufacturer with around 11,600 employees in 2017 for 5.3 billion euros and later took it off the stock exchange. If the IPO succeeds, the pharmaceutical company would return to the floor after seven years of abstinence. The Stada owners have been looking for exit for a long time, but the conversations were recently tough.

The company has prepared a new management structure for the planned IPO, where Stada is advised by Deutsche Bank, among other things: In future, Stada should act under a holding law under a holding law. “Nothing would change at the headquarters in Bad Vilbel in the event of an IPO,” said Goldschmidt.

In the first half of the year, Stada benefited from growing businesses, especially from special medication. In the case of over -the -counter medicines that suffered from a weak cold season and imitators, however, Stada could not grow little. Overall, sales of a currency adjusted by six percent to a good 2.1 billion euros and the adjusted profit before interest, taxes and depreciation (EBITDA) rose five percent to 481 million euros.

Stada had grown in recent years thanks to a series of takeovers, but has accumulated around 5.7 billion euros in debt. In order to become more attractive to investors, the company had split off its Russian business – it was considered a burden on the sales plans. In the event of an IPO, the debt from Stada would halve to Goldschmidt’s words.